摘要
目的:回顾PI3K / AKT / mTOR信号通路的作用以及靶向PI3Ks针对各种疾病(如恶性,自身免疫,炎症,心血管,神经系统疾病等)的当前和未来前景,特别强调炎性疾病和相关的细胞反应。 背景:最近的发现已经将磷酸肌醇-3-激酶(PI3Ks)公布为新的治疗靶点,也被认为参与炎症和各种其他疾病的复杂病理生理学。通过调节各种免疫细胞的生长,发育和增殖,并且因此影响参与这些表现的各种细胞因子和其它炎症介质的释放,它们被认可参与炎性细胞反应。最近有关这种途径与这些疾病有关的文献被强调,希望是PI3K抑制剂在市场上作为治疗选择的进展。 结果:Idelalisib进入癌症市场,PI3K / AKT信号也作为各种疾病,特别是炎症的研究对象,具有重要意义。基于药理学,遗传学和临床资料,PI3K / AKT信号可以被指定为治疗的突出靶点。 结论:进一步探索这一途径也可能揭示其参与这些障碍,这可能进一步有助于开发新的治疗方法,并可能成为未来实验和临床药理学领域创新的脑波。
关键词: 磷酸肌醇-3-激酶(PI3Ks),PI3K抑制剂,炎症,免疫细胞,免疫细胞信号传导,炎性疾病。
图形摘要
Current Drug Targets
Title:Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Volume: 18 Issue: 14
关键词: 磷酸肌醇-3-激酶(PI3Ks),PI3K抑制剂,炎症,免疫细胞,免疫细胞信号传导,炎性疾病。
摘要: Objective: To review the role of PI3K/AKT/mTOR signalling pathway, and the current and future prospects of targeting PI3Ks for various diseases, like malignant, autoimmune, inflammatory, cardiovascular, neurological disorders etc., laying special emphasis on the inflammatory diseases and associated cellular responses.
Background: Recent findings have publicized phosphoinositide-3-kinases (PI3Ks) as novel therapeutic targets, which are also purported to be involved in the complex pathophysiology of inflammatory and various other diseases. They are recognized to participate in the inflammatory cellular responses by modulating the growth, development and proliferation of various immune cells and hence, affect the release of various cytokines and other inflammatory mediators involved in these manifestations. The recent literature relating this pathway with these diseases is highlighted, with a hope, which remains for the progression of PI3K inhibitors in the market as a treatment option.
Result: With Idelalisib entering the market for cancer, PI3K/AKT signalling has also gained significance as an investigational target for various diseases, particularly for inflammation. Based on the pharmacological, genetic, and clinical data available, PI3K/AKT signalling can be designated as an outstanding target for their treatment.
Conclusion: Further exploration of this pathway may also uncover its involvement in these disorders, which may further contribute to developing the new treatments and can turn out to be an innovative brainwave in the field of experimental and clinical pharmacology in future.
Export Options
About this article
Cite this article as:
Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives, Current Drug Targets 2017; 18 (14) . https://dx.doi.org/10.2174/1389450117666161013115225
DOI https://dx.doi.org/10.2174/1389450117666161013115225 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Red Wine Consumption and Prevention of Atherosclerosis: An In Vitro Model Using Human Peripheral Blood Mononuclear Cells
Current Pharmaceutical Design Burkholderia mallei and Burkholderia pseudomallei: The Causative Micro-organisms of Glanders and Melioidosis
Recent Patents on Anti-Infective Drug Discovery Use of Diffusion-Weighted Magnetic Resonance Imaging and Apparent Diffusion Coefficient in Gastric Cancer Staging
Current Medical Imaging Pharmacotherapy for Intermittent Claudication: From Consensus-Based to Evidence-Based Treatment
Vascular Disease Prevention (Discontinued) Current Genomics in Cardiovascular Medicine
Current Genomics Safety of Drug Eluting Stents: Current Concerns and Controversies
Current Drug Safety Patented Biotechnological Applications of Serpin: an Update
Recent Patents on DNA & Gene Sequences Molecular and Cellular Pathways as a Target of Therapeutic Hypothermia: Pharmacological Aspect
Current Neuropharmacology Targeting the Renin-angiotensin System: Whats New?
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Drainage of Cerebral Abscesses Prior to Valve Replacement in Stable Patients with Acute Left-Sided Infective Endocarditis
CNS & Neurological Disorders - Drug Targets Genetic and Molecular Determinants of Atherosclerotic Plaque Instability
Current Vascular Pharmacology Is the Hepatic Factor a miRNA that Maintains the Integrity of Pulmonary Microvasculature by Inhibiting the Vascular Endothelial Growth Factor?
Current Cardiology Reviews Contrast-induced Nephropathy in Non-cardiac Vascular Procedures, A Narrative Review: Part 2
Current Vascular Pharmacology Pharmacoproteomics in Cardiac Hypertrophy and Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets Oxidative Stress and Lipid Peroxidation in Prolonged Users of Methamphetamine
Drug Metabolism Letters Role, Function and Therapeutic Potential of microRNAs in Vascular Aging
Current Vascular Pharmacology The Rise and Fall of NMDA Antagonists for Ischemic Stroke
Current Molecular Medicine Newly Diagnosed Dementia and Increased Risk of Hemorrhagic Stroke: A Nationwide Population-based Study
Current Alzheimer Research Matrix Metalloproteinases as Valid Clinical Target
Current Pharmaceutical Design The Ignored Role of Intraoperative Hypotension in Producing Postoperative Acute Kidney Injury-An Obligatory Appeal for More Preventative Nephrology
Current Hypertension Reviews